Paul Feinstein

Associate
Feinstein Paul
Paul Feinstein is an associate in Venable's Regulatory Practice Group, where he focuses on antitrust matters in a broad range of industries. Paul assists clients on a variety of antitrust issues including government investigations, pre-merger notifications, civil litigation, and strategic counseling. He has particular experience with "reverse payment" litigation and investigations, and Hart-Scott-Rodino ("HSR") matters before the Federal Trade Commission and the Department of Justice.

Paul is a member of the Venable team that is currently defending multiple pharmaceutical manufacturers against "reverse payment" allegations in several jurisdictions. He also works closely with clients to ensure successful compliance with HSR in connection with mergers and acquisitions of all sizes.

Paul has also assisted financial service providers with ongoing regulatory compliance, and telecommunication service providers with communications transactions and regulatory matters throughout the United States. He has particular experience with matters before the Federal Communications Commission and several of the financial services agencies.

Prior to entering law school, Paul was an elementary school teacher in New York City as a corps member of Teach for America.

Experience

Representative Matters

  • Defending Ranbaxy, a Hatch-Waxman "first-filer" generic pharmaceutical company, against a multi-billion-dollar class action (MDL) antitrust "reverse payments" claim in the U.S. District Court for Massachusetts. Obtained a unanimous defense jury verdict after a seven-week trial, in the first "reverse payment" antitrust trial after the U.S. Supreme Court's landmark decision in FTC v. Actavis (In re Nexium [Esomeprazole] Antitrust Litigation)
  • Defending Sun Pharmaceutical Industries Ltd. (which acquired Ranbaxy), a generic pharmaceutical manufacturer, against claims under the Sherman Act arising from alleged "reverse payment" settlement of patent litigation in the Eastern District of Pennsylvania. A highly favorable settlement with retailer and competitor plaintiffs followed a complex four-week jury trial (In re Modafinil Litigation). Successfully defeated certification of the putative direct purchaser class
  • Representing Impax Laboratories, Inc. in "reverse payment" patent settlement cases brought by putative classes of purchasers of Solodyn, an acne treatment drug, and consolidated as an MDL in the U.S. District Court of Massachusetts
  • Representing Impax Laboratories, Inc. in "reverse payment" patent settlement cases brought by putative class purchasers of Opana, an opioid pain medication, in the Northern District of Illinois
  • Representing several different pharmaceutical companies in multiple FTC investigations for alleged antitrust violations involving patent litigation settlements

Insights

Credentials
+

Education

  • J.D. University of Virginia School of Law 2011
    • Articles Editor, Virginia Sports & Entertainment Law Journal
    • Editorial Board, Virginia Journal of Social Policy & the Law
  • B.A. University of Michigan 2006
    • Phi Beta Kappa

Bar Admissions

  • District of Columbia
  • Virginia

Professional Memberships and Activities

  • American Bar Association
  • Virginia State Bar
  • District of Columbia Bar